Search LH
LABCORP HOLDINGS INC.
NYSE · CIK 920148
Last close308.49
Daily change+3.89 (1.28%)
10 Years gain+173.65%
Dividends TTM2.88 (+0.00%)
Dividend yield0.95%
Fundamental Analysis
LH · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
44.8Momentum
60.6Acceleration
59.7Confidence
91.0Annual Revenue20
Quarterly Revenue74
Annual CFO19
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.3 / 25
Quality7.6 / 25
Capital Efficiency6.5 / 20
Balance Sheet7.7 / 15
Shareholder Economics9.8 / 10
Forward Indicators2.0 / 5
Signals
Gross margin expansionGross margin improved by 1.0045 percentage points.
Operating leverageOperating margin improved by 2.1219 percentage points.
ROIC expansionROIC improved by 1.6697 percentage points.
Share count reductionDiluted share count declined 2.7284%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM10.25%OK
Revenue CAGR 3Y5.55%OK
Gross Margin29.23%OK
Operating Margin11.31%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC9.1%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-2.73%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $13.95B | $4.01B | $1.38B | $1.64B | $1.21B | 28.76% | 9.93% | 8.64% | 8.24% | 83.8M |
| 2025 FY Dec 31, 2024 | $13.01B | $3.62B | $1.09B | $1.59B | $1.10B | 27.86% | 8.35% | 8.42% | 6.8% | 84.4M |
| 2025 FY Dec 31, 2023 | $12.16B | $3.36B | $725.60M | $1.33B | $874.10M | 27.67% | 5.97% | 7.19% | 4.17% | 87.6M |
| 2024 FY Dec 31, 2022 | $11.86B | $3.71B | $1.44B | $1.96B | $1.53B | 31.26% | 12.11% | 12.87% | 7.74% | 91.6M |
| 2023 FY Dec 31, 2021 | $13.14B | $4.99B | $3.05B | $3.11B | $2.69B | 38.01% | 23.21% | 20.46% | 17.12% | 97.5M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $14.36B | sum latest 4 fiscal quarters Revenue | OK | 0000920148-26-000175, 0000920148-25-000096 |
| Revenue Growth TTM | 10.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000920148-26-000175, 0000920148-25-000096 |
| Revenue CAGR 3Y | 5.55% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000920148-26-000111 |
| Revenue CAGR 5Y | -0.04% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000920148-26-000111 |
| Gross Profit CAGR 3Y | 2.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000920148-26-000111 |
| Operating Income Growth | 35.72% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0000920148-26-000175, 0000920148-25-000096 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 29.23% | Gross Profit / Revenue | OK | 0000920148-26-000175, 0000920148-25-000096 |
| Operating Margin | 11.31% | Operating Income / Revenue | OK | 0000920148-26-000175, 0000920148-25-000096 |
| ROIC | 9.1% | NOPAT / Average Invested Capital | OK | 0000920148-26-000175, 0000920148-25-000096 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000920148-26-000175 |
| Interest Coverage | 7.08x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1.8x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.02x | (Cash + Short-term Investments) / Total Debt | OK | 0000920148-26-000175 |